Download PDF
Thromb Haemost 2000; 83(06): 909-914
DOI: 10.1055/s-0037-1613943
Commentary
Schattauer GmbH

Proteolytic Modulation of Thrombopoietin Activity: Comparison of Thrombin, Plasmin, and Urokinase

Alexander P. Reiner
1   From the Department of Medicine, University of Washington, Seattle, WA, USA
,
Kaelen M. Aramaki
1   From the Department of Medicine, University of Washington, Seattle, WA, USA
› Author Affiliations
Further Information

Publication History

Received 09 June 1999

Accepted after resubmission 28 January 2000

Publication Date:
14 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Several observations suggest that limited proteolysis of full-length 70 kD human thrombopoietin (Tpo) may be important for Tpo biology. Recently, it was reported that thrombin cleaves full-length recombinant human Tpo (rhTpo) sequentially at two sites, Arg195 within the glycan domain followed by Arg117 within the cytokine domain, and that these cleavages modulate Tpo activity in vitro. We demonstrate that urokinase and plasmin also cleave rhTpo in a time-dependent manner. Urokinase cleavage is confined to the glycan domain, and generates a 35 kD N-terminal fragment that contains the intact cytokine domain, and is associated with increased Tpo activity. In contrast, plasmin cleaves Tpo sequentially at two specific sites (Arg205 within the glycan domain followed by Lys52 within the cytokine domain), and is associated with a marked decrease in Tpo activity. These proteolytic events have potential implications for regulation of Tpo activity in vivo.

Key words

Thrombopoietin - urokinase - plasmin - thrombin - Mpl
 

  • References

  • 1 Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339: 746-54.
    CrossrefPubMedGoogle Scholar
  • 2 de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang W-J, Oles KJ, Hultgren B, Solberg Jr. LA, Goeddel DV, Eaton DL. Stimulation of megkaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-8.
    CrossrefPubMedGoogle Scholar
  • 3 Bartley TD, Bogenberger J, Hunt P, Li Y-S, Lu HS, Martin F, Chang M-S, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu R-Y, Parker VP, Suggs S, Skrine JD, Merewether LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, Choi E, Pangelinan M, Sun Y, Mar V, McNinch J, Simonet L, Jacobsen F, Xie C, Shutter J, Chute H, Basu R, Selander L, Trollinger D, Sieu L, Padilla D, Trail G, Elliott G, Izumi R, Covey T, Crouse J, Garcia A, Xu W, Del Castillo J, Biron J, Cole S, Hu MC-T, Pacifici R, Ponting I, Saris C, Wen D, Yung YP, Lin H, Bosselman RA. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117-24.
    CrossrefPubMedGoogle Scholar
  • 4 Ulich TR, del Castillo J, Yin S, Swift S, Padilla D, Senaldi G, Bennett L, Shutter J, Bogenberger J, Sun D, Samal B, Shimamoto G, Lee R, Steinbrink R, Boone T, Sheridan WT, Hunt P. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971-6.
    PubMedGoogle Scholar
  • 5 Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; a 86: 54-9.
    PubMedGoogle Scholar
  • 6 Linden H, Kaushansky K. The glycan domain of thrombopoietin (TPO) functions alone in trans to enhance secretion of the receptor binding domain of TPO and other cytokines [Abstract]. Blood 1998; 92 (Suppl. 01) 674a.
    PubMedGoogle Scholar
  • 7 Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel T, Wilson J, Steinbrink R, Hecht R, Winters D, Boone T, Hunt P. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486-92.
    PubMedGoogle Scholar
  • 8 Kato T, Ogami K, Shimada Y, Iwamatsu A, Sohma Y, Akahori H, Horie K, Kokubo A, Kudo Y, Maeda E, Kobayashi K, Ohashi H, Ozawa T, Inoue H, Kawamura K, Miyazaki H. Purification and characterization of thrombopoietin. J Biochem 1995; a 118: 229-36.
    CrossrefPubMedGoogle Scholar
  • 9 Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-8.
    CrossrefPubMedGoogle Scholar
  • 10 Shimada Y, Kato T, Ogami K, Horie K, Kokuobo A, Kudo Y, Maeda E, Sohma Y, Akahori H, Kawamura K, Miyazaki H. Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cell lines. Exp Hematol 1995; 23: 1388-96.
    PubMedGoogle Scholar
  • 11 Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-61.
    PubMedGoogle Scholar
  • 12 Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller G-A, de Sauvage FJ, Eaton D. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 2782-8.
    PubMedGoogle Scholar
  • 13 Kato T, Oda A, Inagaki Y, Ohashi H, Matsumoto A, Ozaki K, Miyakawa Y, Watarai H, Fuju K, Kokubo A, Kadoya T, Ikeda Y, Miyazaki H. Thrombin cleaves recombinant human thrombopoietin: One of the proteolytic events that generates truncated forms of thrombopoietin. Proc Natl Acad Sci USA 1997; 94: 4669-74.
    CrossrefPubMedGoogle Scholar
  • 14 Foster DC, Sprecher CA, Grant FJ, Kramer JM, Kuijper JL, Holly RD, Whitmore TE, Heipel MD, Bell LA, Ching AFT, McGrane V, Hart C, O’Hara PJ, Lok S. Human thrombopoietin: Gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci USA 1994; 91: 13023-7.
    CrossrefPubMedGoogle Scholar
  • 15 Foster Donald, Hunt Pamela. The Biological Significance of Truncated and Full-Length Forms of Mpl Ligand. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D. eds. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, New Jersey: Humana Press; 1997: 203-14.
    Google Scholar
  • 16 Pearce Jr KH. Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites. J Biol Chem 1997; 272: 20595-602.
    CrossrefPubMedGoogle Scholar
  • 17 Matsumoto A, Tahara T, Morita H, Usuki K, Ohashi H, Kokubo A, Matsumoto E, Tsunakawa H, Ogami K, Miyazaki H, Urabe A, Kato T. The native human thrombopoietin in blood: Some properties of the endogenous thrombopoietin of the normal and patients with thrombopoietic disorders. Blood 1996; 88: 544a.
    PubMedGoogle Scholar
  • 18 Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-30.
    PubMedGoogle Scholar
  • 19 Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol 1989; 109: 309-15.
    CrossrefPubMedGoogle Scholar
  • 20 Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-95.
    CrossrefPubMedGoogle Scholar
  • 21 Plouët J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272: 13390-6.
    CrossrefPubMedGoogle Scholar